Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cabozantinib s-malate works in treating patients with
osteosarcoma or Ewing sarcoma that has grown or returned (come back) after a period of
improvement. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and may also prevent the growth of new blood vessels that
tumors need to grow.